Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Burning Rock Biotech (BNR) Current Leases (2019 - 2025)

Burning Rock Biotech has reported Current Leases over the past 7 years, most recently at $2.4 million for Q4 2025.

  • For Q4 2025, Current Leases fell 30.9% year-over-year to $2.4 million; the TTM value through Dec 2025 reached $2.4 million, down 30.9%, while the annual FY2025 figure was $2.4 million, 28.79% down from the prior year.
  • Current Leases for Q4 2025 was $2.4 million at Burning Rock Biotech, up from $2.3 million in the prior quarter.
  • Over five years, Current Leases peaked at $5.7 million in Q2 2022 and troughed at $1.2 million in Q4 2023.
  • A 5-year average of $3.8 million and a median of $3.8 million in 2024 define the central range for Current Leases.
  • Biggest five-year swings in Current Leases: surged 653.29% in 2021 and later tumbled 77.1% in 2023.
  • Year by year, Current Leases stood at $5.5 million in 2021, then dropped by 4.36% to $5.2 million in 2022, then tumbled by 77.1% to $1.2 million in 2023, then soared by 185.21% to $3.4 million in 2024, then crashed by 30.9% to $2.4 million in 2025.
  • Business Quant data shows Current Leases for BNR at $2.4 million in Q4 2025, $2.3 million in Q3 2025, and $2.7 million in Q2 2025.